乳がんEC療法における制吐剤の患者による選択と制吐効果の評価
スポンサーリンク
概要
- 論文の詳細を見る
We investigated which antiemetic treatment patients selected during epirubicin /cyclophosphamide (EC) therapy for breast cancer, and assessed the antiemetic efficacy of each treatment using the MASCC Antiemesis Tool (MAT) completed by the patients. After patients received an explanation of antiemetic treatments, including their pharmaceutical prices, they selected and used one of the following four treatments: granisetron+dexamethasone (A), granisetron+dexamethasone+aprepitant (B), palonosetron+dexamethasone (C), or palonosetron+dexamethasone +aprepitant (D). During the first cycle of EC therapy, 50 patients selected one of the four treatments, and morepatients selected Treatments B and C than others: Treatment A was selected by 9 patients (18%), B by 18 (36%), C by 17 (34%), and D by 6 (12%). A total of 198 antiemetic treatments were performed during four cycles of EC therapy: 27 treatments (13.6%) of Treatment A, 81 treatments (40.9%) of B, 62 treatments (31.3%) of C, and 28 treatments (14.1%) of D. Comparing results between Treatment B and C groups, antiemetic rates in acute and late-onset periods and complete response (CR) rates in acute and entire periods in Treatment B group were superior to those in Treatment C group. The results show that none of the treatments provided sufficient nausea control. Since the usefulness of aprepitant, a new antiemetic drug, was demonstrated, but the superiority of palonosetron to granisetron was not determined, and also taking the cost to the patient into consideration, a combination of aprepitant and dexamethasone with one selected 5-HT3 receptor antagonist is recommended.
- 日本医療薬学会の論文
日本医療薬学会 | 論文
- O17-003 視覚障害者に対する手技指導の標準化を目的とした視覚障害擬似体験インスリン注射院内実習(一般演題 口頭発表,糖尿病/後発医薬品,医療薬学の創る未来 科学と臨床の融合)
- 20H-16 Basal-Bolus療法におけるインスリンデテミルの有効性(使用状況調査・意識調査,来るべき時代への道を拓く)
- 30-P2-43 2種類のインスリン試薬を用いた化学発光酵素免疫測定法によってFactitious hypoglicemiaを証明しえた一例(副作用・有害事象,社会の期待に応える医療薬学を)
- 28-04-20 ペン型インスリン注射器の精度に及ぼす注入時抵抗とカートリッジ内気泡の影響
- P-610 ファブリー病に対する「ファブラザイム^[○!R]」投与時の「過敏反応発現時の対処方法」の一部改変により副作用防止に至った1症例(8.有害事象・副作用(基礎と臨床)1,医療薬学の未来へ翔(はばた)く-薬剤師の薬剤業務・教育・研究への能動的関わり-)